title: A case report of improved metabolic control after conversion from everolimus to cyclosporin A: role of adipose tissue mechanisms?
abstract: BACKGROUND
  New-onset diabetes after transplantation is associated with an increase in risk of graft failure, cardiovascular disease, and mortality. Therefore, it compromises the overall beneficial outcome of organ transplantation.
  
  
  METHODS
  A patient with new-onset diabetes after renal transplantation showed glucose and lipid metabolism improvements after switching immunosuppressant from everolimus to cyclosporin A. A subcutaneous adipose tissue biopsy displayed changes in gene and protein expression that could contribute to the clinical improvement of hyperglycemia and dyslipidemia.
authors.affiliation: Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
authors.forename: M J
authors.initials: MJ
authors.lastname: Pereira
authors.affiliation: Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
authors.forename: J W
authors.initials: JW
authors.lastname: Eriksson
authors.affiliation: Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: maria.svensson@wlab.gu.se.
authors.forename: M K
authors.initials: MK
authors.lastname: Svensson
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism*; D000368:Aged; D016572:Cyclosporine / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy; D050171:Dyslipidemias / Q000188:drug therapy; D000068338:Everolimus; D005260:Female; D005947:Glucose; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D005947:Glucose; D020123:Sirolimus